Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1935-1942

  Geng, Qian Qian ^a   Dong, Dan Feng ^a   Chen, Nan Zheng ^a   Wu, Yin Ying ^a   Li, En Xiao ^a   Wang, Jie ^a   Wang, Shao Meng ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Breast cancer; Murine double minute 2; Murine double minute 2 murine double minute X; Murine double minute X; p53

Indexed keywords

NUTLIN 3; NUTLIN 3ALPHA; PROTEIN BAX; PROTEIN DISULFIDE ISOMERASE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; RECOMBINANT PROTEIN; THIOREDOXIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; IMIDAZOLES; MCF-7 CELLS; NUCLEAR PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891933566     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2138     Document Type: Article

References (35)

1. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005.
2. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
3. Ventura A, Kirsch DG, McLaughlin ME, et al: Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665, 2007.
4. Rother K, Kirschner R, Sanger K, Bohlig L, Mossner J and Engeland K: p53 downregulates expression of the G1/S cell cycle phosphatase Cdc25A. Oncogene 26: 1949-1953, 2007.
5. Yu J and Zhang L: The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331: 851-858, 2005.
6. Xue W, Zender L, Miething C, et al: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660, 2007.
7. Crighton D, Wilkinson S, O'Prey J, et al: DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126: 121-134, 2006.
8. Boehme KA and Blattner C: Regulation of p53 - insights into a complex process. Crit Rev Biochem Mol Biol 44: 367-392, 2009.
9. Piette J, Neel H and Marechal V: Mdm2: keeping p53 under control. Oncogene 15: 1001-1010, 1997.
10. Wu X, Bayle JH, Olson D and Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132, 1993.
11. Hock A and Vousden KH: Regulation of the p53 pathway by ubiquitin and related proteins. Int J Biochem Cell Biol 42: 1618-1621, 2010.
12. Marine JC and Jochemsen AG: Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 331: 750-760, 2005.
13. Wiman KG: Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 13: 921-926, 2006.
14. Bond GL, Hu W and Levine AJ: MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8, 2005.
15. Vassilev LT, Vu BT, Graves B, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848, 2004.
16. Hu B, Gilkes DM, Farooqi B, Sebti SM and Chen J: MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 281: 33030-33035, 2006.
17. Toledo F and Wahl GM: MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39: 1476-1482, 2007.
18. Hu B, Gilkes DM and Chen J: Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 67: 8810-8817, 2007.
19. Wu SP, Fu AL, Wang YX, et al: A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase. Biochem Biophys Res Commun 346: 1-6, 2006.
20. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
21. Bottger A, Bottger V, Garcia-Echeverria C, et al: Molecular characterization of the hdm2-p53 interaction. J Mol Biol 269: 744-756, 1997.
22. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
23. Zifou JT and Lowe SW: Tumor suppressive function of p53. Cold Spring Harb Perspect Biol 1: a001883, 2009.
24. Fischer U and Schulze-Osthoff K: New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 57: 187-215, 2005.
25. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2: 985-991, 1996.
26. Clayman GL, el-Naggar AK, Lippman SM, et al: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16: 2221-2232, 1998.
27. Swisher SG, Roth JA, Nemunaitis J, et al: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91: 763-771, 1999.
28. Ritter T, Lehmann M and Volk HD: Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 16: 3-10, 2002.
29. McEvoy J, Ulyanov A, Brennan R, et al: Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS One 7: e42739, 2012.
30. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR and Jackson MW: Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 66: 3169-3176, 2006.
31. Wade M, Wong ET, Tang M, Stommel JM and Wahl GM: Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 281: 33036-33044, 2006.
32. Francoz S, Froment P, Bogaerts S, et al: Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 103: 3232-3237, 2006.
33. Toledo F, Krummel KA, Lee CJ, et al: A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9: 273-285, 2006.
34. Stommel JM and Wahl GM: A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 4: 411-417, 2005.
35. Cai X and Yuan ZM: Stochastic modeling and simulation of the p53-MDM2/MDMX loop. J Comput Biol 16: 917-933, 2009.